Welcome to our dedicated page for Aeluma SEC filings (Ticker: ALMU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aeluma, Inc. filings document the reporting record of a Nasdaq-listed emerging growth semiconductor company developing scalable photonic and electronic technologies. Its periodic and current reports cover financial results, quarterly reporting, Regulation FD materials, investor presentations and public-company disclosure controls.
The company’s SEC filings also describe capital-structure activity involving common stock, shelf registration, underwriting agreements and sales-agreement arrangements for registered equity issuance. Governance disclosures include annual meeting voting results, director elections and shareholder approvals, while other current reports address material definitive agreements and Rule 10b5-1 trading-plan disclosures.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin sold 20,000 shares of common stock in an open-market transaction on April 1, 2026. The shares were sold at a weighted average price of $13.0975 per share, with individual sale prices ranging from $12.82 to $13.325 per share.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2025. Following these transactions, Klamkin directly holds 1,409,398 shares of Aeluma common stock.
Aeluma, Inc. reports a 5.6% stake held by boisei investments llc (via George Perry) totaling 1,000,000 shares of Common Stock. The filing states 1,000,000 shares are beneficially owned with sole voting and dispositive power. The issuer reported 18,002,949 shares outstanding as of March 17, 2026.
The obligation to file was triggered on March 30, 2026 when beneficial ownership was 994,466 shares; the reported amount reflects ownership as of March 31, 2026. George Perry signs as President of boisei investments llc, which is owned through boisei labs llc.
Aeluma, Inc. entered into a Sales Agreement that allows it to issue and sell up to $50.0 million of its common stock from time to time through a group of sales agents. Any shares will be offered under an effective Form S-3 shelf registration statement.
Sales, if made, will occur as ordinary brokers’ transactions on the Nasdaq Capital Market at market prices or as otherwise agreed with the agents. Neither Aeluma nor the agents are obligated to sell or purchase shares, and either party can terminate the agreement with five business days’ written notice.
Aeluma, Inc. has launched an at-the-market offering under a Sales Agreement dated March 20, 2026, authorizing up to $50,000,000 aggregate offering price of common stock. Sales may occur from time to time through Roth Capital Partners as representative and three agent firms, with commissions up to 3%.
The prospectus supplement bases the illustrative share count on 18,002,949 shares outstanding as of March 17, 2026 and shows up to 3,556,187 shares would be issued if $50,000,000 were sold at the March 19, 2026 closing price of $14.06. Proceeds are intended for working capital and general corporate purposes; timing and amounts will vary with market sales.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported open-market sales of a total of 50,000 shares of Aeluma common stock on March 4, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The transactions consisted of 28,206 shares sold at a weighted average price of $17.7746 per share, with individual sale prices ranging from $17.11 to $18.10, and 21,794 shares sold at a weighted average price of $18.4110 per share, with prices ranging from $18.11 to $19.03.
Following these sales, Klamkin directly owned 1,429,398 shares of Aeluma common stock.
ENSLEY CRAIG H reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Craig H. Ensley reported an equity award of 10,633 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. After this grant, he holds 27,300 shares of common stock. The units are scheduled to vest in stages: about 1/12 on December 31, 2025, 1/4 on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Paglia John Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director John Kenneth Paglia reported receiving a grant of 10,861 shares of common stock in the form of restricted stock units at a stated price of $0 per share. Following this award, he holds 23,361 shares directly. The units are scheduled to vest over time: about 1/12 on December 31, 2025, 1/4 each on March 31, June 30, and September 30, 2026, and 1/6 on November 30, 2026.
Aeluma, Inc. director Byron Michael reported receiving equity-based compensation in the form of common stock and stock options. He was granted 13,343 shares of common stock as restricted stock units that are scheduled to vest over several dates through November 30, 2026. The vesting schedule covers approximately 1/12 of the shares on December 31, 2025, 1/4 of the shares on March 31, June 30, and September 30, 2026, and 1/6 of the shares on November 30, 2026. He also acquired stock options for 3,653 shares that are fully vested as of the grant, giving him the right to buy additional common stock.
Denbaars Steven reported acquisition or exercise transactions in this Form 4 filing.
Aeluma, Inc. director Steven Denbaars reported an equity award of 10,121 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this grant, his reported direct holdings total 395,209 shares of common stock.
The restricted stock units are scheduled to vest over several dates: approximately one-twelfth of the shares on December 31, 2025, one-quarter of the shares on March 31, June 30, and September 30, 2026, and the remaining one-sixth on November 30, 2026.